• Pharmx becomes preferred EDI service provider for Sigma wholesale and Chemist Warehouse retail operations
• Sigma to subscribe for 10% of Pharmx shares and obtain a board seat
• Parties to collaborate on global EDI capabilities and digital services

Pharmx Technologies Limited (ASX: PHX) has entered into a binding, multi-year strategic alliance with Sigma Healthcare Limited (ASX: SIG), one of Australia's leading pharmaceutical wholesalers and retail pharmacy operators. The new alliance positions Pharmx as a core technology infrastructure partner to Sigma and the Chemist Warehouse network. Sigma currently services over 3,000 pharmacy customers in Australia including 850 Chemist Warehouse, Amcal and Discount Drug Stores franchises, and over 90 stores across the Republic of Ireland, UAE and New Zealand. As part of the agreement, Pharmx becomes the preferred EDI (Electronic Data Interchange) service provider for Sigma wholesale, and Chemist Warehouse retail operations across Australia and New Zealand. Furthermore, the parties will collaborate on global EDI capabilities and a range of other digital services designed to modernise pharmacy supply chains and support industry-wide efficiency and growth. Pharmx will continue to operate as an independent, whole-of-market solutions provider for the ANZ pharmacy sector, working across all major wholesalers, suppliers, vendors and pharmacies. Sigma will subscribe for approximately 59.95 million Pharmx shares (10% of Pharmx's issued share capital) and will obtain a seat on the Pharmx Board, reinforcing the strategic alignment. Sigma will have the opportunity to subscribe for further Pharmx shares up to an aggregate holding of 19.9% over the term of the alliance, with any such additional issues priced at the 30-day volume weighted average price prior to the relevant issue and subject to Pharmx shareholder approval to the extent required.

The incremental financial impact of the strategic alliance is not quantifiable until future statements of works have been defined and agreed by both parties.

The strategic alliance agreement has the potential to broaden Pharmx's revenue profile, expand its footprint across ANZ, and establish a foundation for future global expansion. These opportunities result from the investments Pharmx has made in strengthening its Gateway, launching Marketplace, and accelerating its analytics strategy.